



ZAHRA MADJD, MD PhD

PERSONAL DETAILS

Dep of Pathology, Faculty of Medicine
 Dep of Molecular Medicine, Faculty of Advanced Technologies in Medicine
 Oncopathology Research Centre, Iran University of Medical Sciences (IUMS)
 Hemmat Highway, Next to Milad tower, Tehran, Iran
 Post code: 14496-14525
 Tel/fax:+982188622608
Zahra.madjd@yahoo.com, madjd.z@iums.ac.ir

Academic Activities

Position	Dates	Place
Associate Professor	Sep 2012- present	Dep Pathology, Iran University of Medical Sciences (IUMS)
Head, Cancer Stem Cells Committees	January 2016-present	National Committee for Stem Cell Sciences and Technologies
Sabbatical , visiting scientist	May-June 2014 December 2014- March 2015	Molecular Medicine Lab, Dep Dermatology, University of British Columbia, Vancouver, Canada
Member of National Board on Biotechnology and Molecular Medicine	October 2013-present	Ministry of Health and Medical Education
Head Dep. Molecular Medicine	2009- present	Iran University of Medical Sciences
Research Director of Oncopathology Research Centre	2007 - present	Iran University of Medical Sciences
Head of Research Centres Coordinating Office (RCCO)	April- Oct 2013	Iran University of Medical Sciences
Core member of Cancer Research Centre (CRC)	2007 - present	Shahid Beheshti University, Shohada Hospital, Tehran
Member of Research Committee	2007- present	Dep Pathology, Iran University of

		Medical Sciences
Scientific committee of Cellular Molecular Research Centre	2007- present	Iran University of Medical Sciences
Member of Scientific committee of Razi Drug Research Centre,	2009- 2014	Iran University of Medical Sciences
Assistant Professor	August 2006- Sep 2012	Dep of Pathology, IUMS

Previous appointments

Dates	Description of qualification	Place obtained
1988 -1996	Doctorate in Medicine	Tehran, Iran
1996- 2000	Medical practice as GP	Tehran, Iran
2000-2001	Courses in MSc Oncology	University of Nottingham, UK
2001- 2005	PhD, Cancer Immunology (Supervisors: Prof Lindy Durrant and prof Ian. O Ellis)	CRUK Clinical Oncology, University of Nottingham, City Hospital, Nottingham, UK
2005-2006	Post-doctoral Research Fellow (Prof Lindy Durrant)	CRUK Clinical Oncology, University of Nottingham, City Hospital, Nottingham, UK
2006	Appointed for Career Development Fellowship, Post doctorate Scientist	University of Cambridge, Addenbrock's Hospital, MRC

Grants

1. National Major Grant, Research and Technology Office, Ministry of Health and Medical Education, for “Cancer Stem Cells in Gastrointestinal Cancers” equipment setup (March 2016)
2. Research Grant, Research and Technology Office, Ministry of Health and Medical Education, to equip a special culture room for Cancer Stem Cell Research (Dec 2015)
3. Grant by “Iran National Science Foundation: for project on Renal Cancer Stem Cells (Oct 2015)
4. Grants by “Natal Institute for Medical Reserch Development”, as distinguished researcher with high H-Index (Feb 2016, 2017)

Honours and Prizes

- EACR-18 (European Association of Cancer Research) award, July 2004, Insbruck, Austria.
- BACR (British Association of Cancer Research) award , ECCO13 meeting, October 2005, Paris
- BACR award at the EACR 20, July 2008, Lyon, France
- Young Researcher award, Iranian Ministry of Health and Education, December 2008
- Distinguished Researcher award , Iran University of Medical Sciences, Dec 2014

Editorial Board / Reviewer:

- Cancer Letters
- Stem Cells
- Cancer Research
- PLOS ONE
- Tumour Biology
- Future Oncology
- Expert Opinion On Therapeutic Targets
- Case Reports in Oncological Medicine, USA
- Journal of Solid Tumours, Canada
- Iranian Journal of Cancer Prevention (IJCP), Iran
- Razi Journal of Medical Sciences (RJMS) , Iran
- Medical Journal of The Islamic Republic of Iran (MJIRI), Iran
- Basic & Clinical Cancer Research, Iran

Memberships

- BACR (British Association for Cancer Research)
- EACR (European Association for Cancer Research)
- ISSCR (International Society for Stem Cell Research)

Research Interests:

- Cancer Stem cells
- Targeted therapy, vaccine for Cancer Stem cells
- Circulating Tumour Cells
- Translational Cancer Research
- Biomarkers of solid tumours (breast cancer, prostate cancer, lung cancer, melanomas)

Background Education:

1. MD dissertation: “Characteristics of thyroid disorders before and after iodized salt consumption in Tehran during 1993-5”. **Supervisor: Professor Freidoon Azizi**

2. PhD projects: Expression of complement regulatory proteins (CIPs) and MHC class I molecules in breast carcinomas. These antigens (CIPs) are targets for monoclonal antibody therapy (mab), as over-expression of CIPs limits the effectiveness of mab therapy. **Supervisors: Prof Lindy Durrant & Prof an Ellis, University of Nottingham, UK**

3. Post-doctoral Research Fellow, University of Nottingham, City Hospital, Dep. Of Clinical Oncology

Outline of study: Study of immune-surveillance pathway in Breast tumours, colorectal cancer, supervisor: Prof Lindy Durrant

4. Appointed for Career Development Fellowship, Post doctorate Scientist, University of Cambridge, Addenbrock's Hospital, MRC Dunn Human Nutrition Unit, Diet and Cancer research group (Not completed)

Outline of study: DNA adducts, differences in gene expression and DNA damage and histochemistry of tumour samples, Supervisor: Shila Bingham

5. **Visiting Scientist, Molecular Medicine Lab**, Dep Dermatology, University of British Columbia, Vancouver, Canada

Outline of Study, Biomarkers in Melanoma

PUBLICATIONS:

h- Index (Scopus) =17

h- Index (Google scholar) =21

2017

1. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells, Alireza Korourian¹, Raheleh Roudi², Ahmad Sharifabrizi³, **Zahra Madjd**, Experimental Biology and Medicine, 2017.
2. Cancer Stem Cell Research in Iran: Potentials and Challenges, Raheleh Roudi, Marzieh Ebrahimi, Ahmad Sharifabrizi, **Zahra Madjd**, Future Oncology, 2017
3. Cancer stem cell's potential clinical implications, Mirzaei, A., **Madjd, Z.**, Kadijani, A.A., (...), Akbari, A., Tavoosidana, G., Iranian Journal of Cancer Prevention, 2017
4. Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas, : Pathology oncology research, Kalantari E, Asgari M, Nikpanah S, Salarieh N, Asadi Lari MH, **Madjd Z**, 2017
5. Possible involvement of CREB/BDNF signaling pathway in neuroprotective effects of topiramate against methylphenidate induced apoptosis, oxidative stress and inflammation in isolated hippocampus of rats: Molecular, biochemical and histological evidences Motaghinejad M, Motevalian M, Babalouei F, Abdollahi M, Heidari M, **Madjd Z**. Brain Res Bull. 2017 May 24;132:82-98
6. Topiramate Confers Neuroprotection Against Methylphenidate-Induced Neurodegeneration in Dentate Gyrus and CA1 Regions of Hippocampus via CREB/BDNF Pathway in Rats, Neurotoxicity research, Motaghinejad M, Motevalian M, Abdollahi M, Heidari M, Madjd Z. 2017
7. Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma. A Rasti, M Abolhasani, LS Zanjani, M Asgari, M Mehrazma, Z Madjd. Journal of Cancer Research and Clinical Oncology, 2017, 1-10

8. Evaluation of circulating cellular DCLK1 protein, as the most promising colorectal cancer stem cell marker, using immunoassay based methods. A Mirzaei, Z Madjd, AA Kadijani, M Tavakoli-Yaraki, MH Modarresi, *Cancer Biomarkers*, 2016, page 1-11
9. Differential role of Wnt signaling and base excision repair pathways in gastric adenocarcinoma aggressiveness. Korourian A, Roudi R, Shariftabrizi A, Kalantari E, Sotoodeh K, **Madjd Z**. *Clin Exp Med*. 2016 Dec 1
10. Coenzyme Q10 Ameliorates Trimethyltin Chloride Neurotoxicity in Experimental Model of Injury in Dentate Gyrus of Hippocampus: A Histopathological and Behavioral Study. MH Sakhaie, M Soleimani, V Pirhajati, SS Asl, Z Madjd, M Mehdizadeh. *Iranian Red Crescent Medical Journal*, 2016
11. Probiotic feeding affects T cell populations in blood and lymphoid organs in chickens. Asgari F, **Madjd Z**, Falak R, Bahar MA, Nasrabadi MH, Raiani M, Shekarabi M. *Benef Microbes*. 2016 Jun 28:1-8
12. Expression of CD133 cancer stem cell marker in melanoma: a systematic review and meta-analysis. **Zahra Madjd**, Elham Erfani, Elmira Gheytauchi, Maziar Moradi-Lakeh, Ahmad Shariftabrizi, Mohsen Asadi-Lari. *Int J Biol Markers* 2016.
13. Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma. Roudi R, Madjd Z, Ebrahimi M, Najafi A, Korourian A, Shariftabrizi A, Samadikuchaksaraei A. *Tumour Biol*. 2016 Apr 5.
14. Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas. Sedaghat S, Gheytauchi E, Asgari M, Roudi R, Keymoosi H, **Madjd Z**. *Appl Immunohistochem Mol Morphol*. 2016 Mar 3.
15. Accuracy of c-KIT in Lung Cancer Prognosis; a Systematic Review Protocol" .Roudi R, Kalantari E, Keshtkar A, **Madjd Z**. *Asian Pac J Cancer Prev*. 2016;17(2):863-6.
16. Increased Expression of ALDH1A1 in Prostate Cancer is Correlated With Tumor Aggressiveness: A Tissue Microarray Study of Iranian Patients. Kalantari E, Saadi FH, Asgari M, Shariftabrizi A, Roudi R, **Madjd Z**. *Appl Immunohistochem Mol Morphol*. 2016 Feb 18.
17. Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: a systematic review protocol. Rasti A, Mehrazma M, **Madjd Z**, Keshtkar AA, Roudi R, Babashah S. *BMJ Open*. 2016 Jan
18. Impaired Memory and Evidence of Histopathology in CA1 Pyramidal Neurons through Injection of A β 1-42 Peptides into the Frontal Cortices of Rat. Eslamizade MJ, **Madjd Z**, Rasoolijazi H, Saffarzadeh F, Pirhajati V, Aligholi H, Janahmadi M, Mehdizadeh M. *Basic Clin Neurosci*. 2016 Jan;7(1):31-41.

19. Evaluation of anaplastic lymphoma kinase (ALK) expression in nonsmall cell lung cancer; a tissue microarray analysis. Raheleh Roudi, Gholamreza Haji, **Zahra Madjd**, Ahmad Sharifabrizi, Mitra **Mehrazma**. Journal of Cancer Research and Therapeutic. 2016

2015

20. Comparative gene-expression profiling of CD133⁺ and CD133⁻ D10 melanoma cells. Roudi R, Ebrahimi M, Sabet MN, Najafi A, Nourani MR, Fomeshi MR, Samadikuchaksaraei A, Sharifabrizi A, **Madjd Z**. Future Oncol (IF=2.5). 2015 Aug 19:1-11 (Corresponding author)
21. A new insight into cancer stem cell markers: Could local and circulating cancer stem cell markers correlate in colorectal cancer? Mirzaei A, Tavoosidana G, Rad AA, Rezaei F, Tavakoli-Yaraki M, Kadijani AA, Khalili E, **Madjd Z**. Tumour Biol. 2015 Sep 17
22. Comparative expression analysis of putative cancer stem cell markers CD44 and ALDH1A1 in various skin cancer subtypes, Elham Erfani¹, Raheleh Roudi, Azadeh Rakhshan, Mehrdad Nasrollahzadeh Sabet, Ahmad Sharifabrizi, Zahra Madjd, Int J Biomedical Markers. 2015. (Corresponding author)
23. A Simple, Rapid, and Efficient Method for Isolating Mesenchymal Stem Cells from the Entire Umbilical Cord. Dehkordi MB, **Madjd Z**, Chaleshtori MH, Meshkani R, Nikfarjam L, Kajbafzadeh A. Cell Transplant. 2015 Aug 12 (Corresponding author)
24. PI3K/Akt inhibition and down-regulation of BCRP re-sensitize MCF7 breast cancer cell line to mitoxantrone chemotherapy. Komeili-Movahhed T, Fouladdel S, Barzegar E, Atashpour S, Hossein Ghahremani M, Nasser Ostad S, **Madjd Z**, Azizi E. Iran J Basic Med Sci. 2015 May;18(5):472-7.
25. Differential expression of cancer stem cell markers ALDH1 and CD133 in various lung cancer subtypes, Raheleh Roudi, Alireza Korourian, Ahmad Sharifabrizi, and **Zahra Madjd**. Cancer Invest (IF=2.06). 2015 Jun 5. (corresponding Author)
26. Study of NGEP expression in androgen sensitive prostate cancer cells: A potential target for immunotherapy. Mohsenzadegan M, Tajik N, **Madjd Z**, Shekarabi M, Farajollahi MM. Med J Islam Repub Iran. 2015 Jan 13;29:159
27. Study of NGEP expression pattern in cancerous tissues provides novel insights into prognostic marker in prostate cancer. Mohsenzadegan M, Shekarabi M, **Madjd Z**, Asgari M, Abolhasani M, Tajik N, Farajollahi MM. Biomark Med (IF=2.5). 2015; 9(4):391-401.
28. Effect of Copper Sulfate on Expression of Endogenous L1 Retrotransposons in HepG2 Cells (Hepatocellular Carcinoma). Karimi A, Majidzadeh-A K, **Madjd Z**, Akbari A, Habibi L, Akrami SM. Biol Trace Elem Res (IF=1.5). 2015 Jun;165(2):131-4.
29. Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients. Mirzaei A, Tavoosidana G,

Modarressi MH, Rad AA, Fazeli MS, Shirkoohi R, Tavakoli-Yaraki M, **Madjd Z**. Tumour Biol. (IF=2.8) 2015 Jan 29. (Corresponding author)

2014

30. Tissue microarrays, a revolution in pathology research, Elham Kalantari , **Zahra Madjd**, BCCR, 2014. (Corresponding author).
31. Prognostic relevance of putative cancer stem cell marker, CD44 in different histological sub-types of lung cancer. Raheleh Roudi, **Zahra Madjd**, Alireza Korourian, Mitra Mehrazma, Ahmad Shariftabrizi, SaadatMolanae. Cancer Biomarkers 14 (2014) 457–467 (IF= 1.18) (Corresponding author).
32. Co-Expression of Putative Cancer Stem Cell Markers, CD133 and Nestin, in Skin Tumors. Mehrdad Nasrollahzadeh Sabet , Azadeh Rakhshan , Elham Erfani , **Zahra Madjd**, Asian Pac J Cancer Prev, 15 (19), 8161-8169. (IF= 1.27) (Corresponding author
33. Tissue Microarray-based investigation PLAC1 expression in Prostate Carcinoma. Roya Ghods, Mohammad Hossein Ghahremani, **Zahra Madjd** , Mojgan Asgari Maryam Abolhasani, Sanaz Tavassoli , Ahmad Reza Mahmoudi, Mahmood Jeddi-Tehrani, Maryam Darzi, Amir-Hassan Zarnani, Cancer Immunology Immunotherapy (IF=3.94), 2014 Sep 4.
34. A comparative study of mesenchymal stem cell transplantation with its paracrine effect on control of hyperglycemia in type 1 diabetic rats. Aali E, Mirzamohammadi S, Ghaznavi H, **Madjd Z**, Larijani B, Rayegan S, Sharifi AM.J Diabetes Metab Disord. 2014 Aug 11;13(1):76. doi: 10.1186/2251-6581-13-76.
35. Exposure of hepatocellular carcinoma cells to low-level As₂O₃ causes an extra toxicity pathway via L1 retrotransposition induction. Karimi A, **Madjd Z**, Habibi L, Akrami SM. Toxicol Lett(IF=3.5). 2014 Jun 21; 229(1):111-117.
36. Evaluating the Extent of LINE-1 Mobility Following Exposure to Heavy Metals in HepG2 Cells. Karimi A, **Madjd Z**, Habibi L, Akrami SM. Biol Trace Elem Res (IF=1.5). 2014 Jul;160 (1):143-51. 2014 Jun 5. (Corresponding Author)
37. Expression of Ki-67, p53 and VEGF in pediatric neuroblastoma. Gheytauchi E, Mehrazma M, **Madjd Z**. Asian Pac J Cancer Prev (IF=1.27). 2014; 15 (7): 3065-70.
38. ALDH1 in combination with CD44 as putative cancer stem cell markers are correlated with poor prognosis in urothelial carcinoma of the urinary bladder. Keymoosi H, Gheytauchi E, Asgari M, Shariftabrizi A, **Madjd Z**. Asian Pac J Cancer Prevention (IF=1.27). 2014; 15(5):2013-20. (Corresponding author)
39. Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumour size in breast carcinomas. **Zahra Madjd**, Mohammad E. Akbari; Amir Hassan Zarnani, Maryam Khayam zadeh, Elham Kalantari, Nazanin Mojtavavi., Asian Pacific J Can Prevention(IF=1.27), Volume 14, Issue 4 (Corresponding author)

2013

40. The expression of p53 and MDM4 in oral, laryngeal and cutaneous squamous cell carcinoma: A comparative study by tissue microarray Sami Jabar, Seta Sarkis, **Zahra Madjd**, Elham Kalantari, European Scientific Journal, December 2013
41. CD44 and CD24 markers cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549. Raheleh Roudi. Marzieh Ebrahimi, Ali Samadikuchaksaraei, **Zahra Madjd**. CELLULAR & MOLECULAR BIOLOGY LETTERS (IF=1.9), 13 Dec 2013. (Corresponding author)
42. Evaluation of methylation of MGMT (O⁶- methyl guanine methyltransferase) gene promoter by Methylation Specific-PCR in meningiomas with atypical features and its comparison between tumor grades I, II, and III, Leila Larijani, **Zahra Madjd** et al, accepted to be included in Asian Pacific J Can Prevention (IF=1.27), Volume 14, Issue 2.
43. Expression of prostate stem cell antigen (PSCA) in prostate cancer; a tissue microarray study of Iranian patients. Jaleh Taeb, Mojgan Asgari, Maryam Abolhasani, Mohammad M Farajollahi, **Zahra Madjd**. Pathol Res Pract (IF=1.4). 2013 Oct 11 (Corresponding author)
44. Reduced expression of NGEP is associated with high grade prostate cancers: a tissue microarray analysis. Monireh Mohsenzadegan , **Zahra Madjd**, Mojgan Asgari, Maryam Abolhasani, Mehdi Shekarabi , Jaleh Taeb, Ahmad Sharifatabrizi, Cancer Immunology Immunotherapy, Cancer Immunology Immunotherapy (IF=3.94). 2013 Oct; 62 (10) (Corresponding author)
45. Application of Stem Cells in Targeted Therapy of Breast Cancer: A Systematic Review. **Madjd Z**, Gheytanchi E, Erfani E, Asadi-Lari M. Asian Pac J Cancer ev. 2013;14(5):2789-2800. (Corresponding Author)
46. Chronic Ritalin Administration during Adulthood Increases Serotonin Pool in Rat Medial Frontal Cortex. Daniali S, Nahavandi A, **Madjd Z**, Shahbazi A, Niknazar S, Shahbazzadeh D. Iran Biomed J. 2013 Jul;17(3):134-9.
47. Expression of stem cell markers, CD133 and CD44 in pediatric solid tumours, a study using Tissue microarray. Mitra Mehrasma, Zahra Madjd, Elham Kalantari, Mahshid Panahi, Alireza Hendi. Fetal Pediatr Pathol. 2013 Jun; 32(3):192-204.

2012

48. High expression of stem cell marker ALDH1 is associated with mutated BRCA1 in invasive breast carcinomas, **Zahra Madjd**, Babak Ramezani , Mohsen Asadi Lari, Saadat Molanae, Asian Pac J Cancer Prev. 2012;13(6):2973-8 (Corresponding Author)

49. Do clinical and demographic features of patients with upper-gastrointestinal cancer affect their health-related quality of life? Ali Esmaili-Hesari, Fatemeh Homai, Abbas Motevallian, **Zahra Madjd**, Masoud Solaymani-Dodaran, Mohsen Asadi-Lari. *Int J Prev Med.* 2012 Nov; 3(11):783-90.
50. The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays. Sotoudeh K, Hashemi F, **Madjd Z**, Sadeghipour A, Molanaei S, Kalantari E. *Diagn Pathol.* 2012 May 28; 7:57.
51. Apelin-13 Protects the Brain Against Ischemic Reperfusion Injury and Cerebral Edema in a Transient Model of Focal Cerebral Ischemia. Khaksari M, Aboutaleb N, Nasirinezhad F, Vakili A, **Madjd Z**. *J Mol Neurosci.* 2012 Sep;48(1):201-8.

2011

52. Occult Hepatitis C Virus Infection in Iranian Patients with Chronic Liver Disease with Unknown Etiology, Farah Bokharaei Salim, Hossein keyvani, Seyed Moayed Alavian, Seyed Hamid Reza Monavari **Zahra Madjd**, Mohsen Nasiri Tousi, Amir Houshang Alizadeh. *Journal of Medical Virology*, 2011, June (IF=2.5).
53. Neuroprotective Effect of Exogenous Melatonin on Dopaminergic Neurons of the Substantia Nigra in Ovariectomized Rats. Fereshteh Mehraein, Reza Talebi, Behnamedin Jameie, Mohammad Taghi Joghataie and Zahra Madjd, *Iranian Biomedical Journal* 15 (1 & 2): 44-50 (April & January 2011).
54. BRCA1 protein expression level and CD44+ phenotype in breast cancer patients. **Zahra Madjd**, Adel Karimi, Saadat Molanae, Mohsen Asadi-Lari. *CELL JOURNAL (Yakhteh)*, Vol 13, No 3, Autumn 2011 (Corresponding Author)
55. Immunohistochemical localization of endothelial nitric oxide synthase in testicular cells of men with non- obstructive azospermia, Khadijeh Foghi , Marefat Ghaffari Novin., **Zahra Madjd**, Tohid Najafi., Mohammad Hasan Heidari., Abouzar Rostampour Yasoori. *Iranian Journal of Reproductive Medicine* Vol.9. No.4. pp:277-280, Autumn 2011.
56. Expression of BRCA1 Protein in Invasive and In Situ Carcinomas and its Relation with Marker of Breast Cancer Stem Cells (CD44) and Prognostic Factors in Breast Cancer Patients. **Madjd Z**, Karimi A, Hashemi F, Molanae S, *Razi Journal of Medical Sciences* Vol. 17, No. 80 & 81, Feb/Mar 2010-2011 (In Persian)
57. The immunohistochemical assessment of ALDH1 activity in breast cancer and it's correlation with pathologic features. Babak Ramezani, Zahra Madjd, Maryam Kadivar, Saadat Molanae. *Tehran University Medical Journal*; Vol. 69, No. 9, December 2011: 529-536(In Persian)

2009

58. CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. Madjd Z, Zare Mehrjerdi A, Sharifi A, Molanaei S, Zohourian S, Asadi Lari M. *Cancer Immunity*. April 2009.vol9.p4.
59. The Concept of Palliative Care Practice among Iranian General Practitioners. Asadi-Lari M, Madjd Z, Afkari ME, Goushegir A, Baradaran HR. . *Iranian Journal of Cancer Prevention*. Vol.2, No 3, summer 2009.
60. OCT4, an embryonic stem cell marker, is expressed in breast, brain and thyroid carcinomas compared to testicular carcinoma. Madjd Z, Hashemi F, Shayanfar N, Farahani E, Zarnani AH, Sharifi AM. *Iranian Journal of Cancer Prevention*. Vol.2, No 4, autumn 2009.

2008

61. The need for palliative care services in Iran; an introductory commentary. Asadi-Lari M, Madjd Z, Akbari ME. *Iranian Journal of Cancer Prevention*. Vol.1, No1, 1-5, .2008. Jan
62. Spiritual care at the end of life in the Islamic context, a systematic review, Asadi-Lari M, Madjd Z, Goushegir. *Iranian Journal of Cancer Prevention*. Vol.1, No 2, July 2008.
63. Gaps in the provision of spiritual care for terminally ill patients in Islamic societies, a systematic review. Mohsen Asadi-Lari, Zahra Madjd, Sayyed Ashrafeddin Goushegir. *Advances in Palliative Medicine* 2008, 73–80.

2007

64. The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Rolland P, **Madjd Z**, Durrant L, Ellis IO, Layfield R, Spendlove I. *Endocrine Related Cancer* (IF: 5.193). 2007 Mar;14(1):73-80.
65. Up-regulation of MICA on high-grade breast carcinomas. **Madjd Z**, Pinder SE, Spendlove I, Watson NFS, Moss R, Bevan S, Durrant LG. *Cancer immunity*, 2007

2006

66. Expression of the stress related protein MICA is an independent indicator of good prognosis in colorectal cancer patients. Watson NFS, Spendlove I, **Madjd Z**, Moss R, Green A, Ellis IO, Durrant LG, Scholefield JH. *International J Cancer* (IF: 5.007). 2006 Mar 15; 118(6):1445-52.
67. Cytoplasmic expression p27^{KIP-1} is associated with a favourable prognosis in colorectal cancer patients. NFS Watson, LG Durrant, JH Scholefield, **Z Madjd**, D Scrimgeour, I Spendlove, IO Ellis, PM Patel. *World J Gastroenterology* (IF=2.433). 2006 Oct 21,12(39).

68. The p53 Positive Bcl-2 Negative Phenotype is an independent marker of prognosis in breast cancer. Phil Rolland, Ian Spendlove, **Zahra Madjd**, Emad A Rakha, Patel Poulam, Ian O. Ellis, Lindy Durrant. International J Cancer (IF: 5.007), 22 Dec 2006 .
69. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC Class I expression correlates with a poor prognosis in early stage patients. Watson NFS, Ramage J, **Madjd Z**, Spendlove I, Ellis IO, Scholefield J, Durrant LG. Int J Cancer (IF: 5.007) . 2006 Jan 1; 118(1): 6-10.

2005

70. Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: A tissue microarray study of 460 patients. Watson NFS, **Madjd Z**, Ellis IO, Scholefield J, Spendlove I. Durrant LG. World J Surg Oncology (IF: 1.20). 2005 Jul 19; 3:47.
71. Expression of the Membrane Complement Regulatory Protein CD59 (Protectin) is Associated with Reduced Survival in Colorectal Cancer patients. Watson NFS, Durrant LG, **Madjd Z**, Ellis IO, Scholefield J, and Spendlove I. Cancer Immunology Immunotherapy (2007 IF: 3.94) . 2005 Sep 3;1-8
72. Over-expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. **Madjd Z**, Parsons T, Watson NFS, Spendlove I, Ellis IO and Durrant LG. Breast Cancer Research. (IF: 5.88); 7(5):R780-7. 2005 Jul 28.
73. Do poor prognosis breast tumours express membrane cofactor proteins (CD46)? **Madjd Z**, Durrant LG, Pinder SE, Ellis IO, Ronan J, Rushmere NK and Spendlove. Cancer Immunology Immunotherapy (IF: 3.94), 2005;54(2):149-56
74. Total loss of MHC class I molecules is an independent indicator of good prognosis in breast cancers. **Madjd Z**, Pinder SE, Spendlove I, Ellis IO, and Durrant LG. International J Cancer (IF: 5.007). 2005 Nov 1; 117(2): 248-55.

2003- 2004

75. Loss of CD55 is associated with aggressive breast tumours. **Madjd Z**, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE. Clinical Cancer Research (IF: 8.193), 2004, 10: 2797-2803
76. Loss of CD59 expression in breast tumours correlates with poor survival. **Madjd Z**, Pinder S E, Paish C, Ellis IO, Carmichael J, Durrant L G. J Pathology.(IF: 7.33), 2003, 200: 633-639.

Book:

1. Cancer and Immune system in "**Iran Cancer Report**", in Farsi, 2008, By Cancer Research Centre, Shahid Beheshti University of Medical Sciences
2. **Tissue Microarrays, Evolutionary in Pathology Research**, in Farsi, 2009, By Oncopathology Research Centre, IUMS
3. **What we should know about Breast Cancer**, hundreds questions and answers about Breast cancer , in Farsi, 2010, Oncopathology Research Centre, IUMS
4. **Complement Regulatory Proteins in Breast Cancer**, Madjd Z and Durrant LG In English, 2010, ISBN (978-3-8383-3769-2), published by LAP LAMBERT Academic Publishing AG & Co. KG, Germany, Distribution by Amazon. www.amazon.com

Selected ongoing project:

1. The effect of cancer stem cell-based vaccine on tumour phenotype in mice colorectal model (Supervision of postdoc- IUMS)
2. Evaluation of Migration and Anti-tumor Activity of CD19-CAR (**chimeric antigen receptor**) T Cells Overexpressing CXCR4 (PhD project, having joint with Paul-Ehrlich- Institute, Germany)
3. Evaluation of biological characteristics and telomerase activity in cancer stem cells (CSCs) compared with non- CSCs (low tumorigenic cells) in renal cancer (PhD project, joint project with Oslo University, Norway)
4. Investigation and comparison of gene expression profiles of circulating tumor cells (CTCs) and circulating exosomes in treated patients with metastatic colorectal cancer (supervisor of PhD, IUMS, joint project with Royan Institute)
5. The expression of a novel cancer stem cell marker, DCLK1 in Transitional bladder carcinomas: a tissue microarray study (supervisor of pathology resident)
6. The effect of silencing of transcription factor SMAD4 on stemness characteristics of cancer stem cells compared with non- CSCs (low tumorigenic cells) in renal cancer (supervisor of PhD, IUMS)
7. The systemic effects of regulatory factors (LncRNA , miRNA) on expression of genes and proteins in cancer stem cells (CSCs) compared to parental cells of colorectal carcinomas (supervisor of PhD, IUMS)
8. Evaluation of the ability of colorectal cancer stem cells (CSCs) lysate-pulsed dendritic cells in induction of cytotoxic T lymphocytes against CSCs as compared to their parental cells (supervisor of PhD, IUMS)
9. Study the effect of exosomes secreted from CSCs of invasive colorectal cancer cell line (HT-29) on drug resistance and invasion of Caco-2 cell line (supervisor of PhD, IUMS)

10. Expression of exosomal marker TSG101 in colorectal carcinoma and its correlation with clinicopathologic findings
11. Study of Circulating Breast Cancer stem cells (GD2+, CD44+/ CD24-), for monitoring breast cancer patients, before and after treatment (supervisor of PhD, IUMS)

Completed projects (selected):

- 1) In vitro study of the role of microRNA-31 (miR-31) in mediating 5-FU chemo-resistance and metastasis of gastric cancer cell line (AGS) (PhD thesis, Molecular Medicine, Iran University of Medical Sciences)
- 2) Application of colorectal cancer stem cell markers (DCLK1 & Lgr5) in blood and tissue to monitor the patients, using Ligand Proximity Assay (PhD thesis, Tehran University of Medical sciences)
- 3) Gene expression and protein detection of cancer stem cells of Melanoma, skin squamous cell and basal cell carcinoma compared to non-tumorigenic cells using cDNA microarrays and tissue microarrays (Supervision of PhD thesis, Molecular Medicine, IUMS, joint project with Royan Institute)
- 4) Comparison of gene expression and protein detection of cancer stem cells (Tumorigenic) with non-tumorigenic lung cancer cells (PhD, Molecular Medicine, IUMS, joint project with Royan Institute)
- 5) Molecular imaging of prostate cancer by magnetic nanoprobe conjugated anti-PSCA antibody and assessment of PSCA expression in prostate cancer tissues (PhD, Molecular Medicine, IUMS)
- 6) Analysis the induction of L1 Retrotransposon and toxicity by heavy metals on NSCs (H9 hESC-Derived) (PhD, Molecular Medicine, IUMS)
- 7) Differentiation of umbilical cord stem cells into Germ cells (PhD thesis, Tehran University of Medical sciences)
- 8) Clinical significance of ALDH1 and CD44 as cancer stem cell markers in Bladder carcinomas (Supervisor of resident (SpR) of Pathology, IUMS)
- 9) Investigation of OCT4, as an embryonic stem cell marker and its correlation with clinicopathological parameters in bladder carcinomas (Supervisor of resident (SpR) of Pathology, IUMS)
- 10) Methylation of promotogene MGMT(O⁶- methyl guanine methyl transferase) in Atypic Meningioma compared to Grade I, II and III tumours (supervisor of MSc, Genetic, Azad University, finished)
- 11) Expression of BRCA₁ protein and its relation with markers of breast cancer stem cells (CD44) and prognostic factors in breast cancer patients (Supervisor of resident (SpR) of Pathology, IUMS)
- 12) Immunohistochemical assessment of ALDH1 enzyme activity as a functional marker of stem cells and precursor cells of breast (Supervisor of resident (SpR) of Pathology)
- 13) Expression of OCT4 using immunohistochemistry and its association with clinico-pathological features of bladder transitional cell carcinoma (Supervisor of resident (SpR) of Pathology, IUMS, finished)
- 14) Targeting extracellular domain of NGEF using polyclonal antibody in prostate cancer (PhD of Immunology, IUMS)

- 15) Molecular study of effect of siRNA on expression and function of BCRP and the role of PI3K/AKT pathway in reducing drug resistance to Mithoxantron in stem cell and non stem cells of breast and colorectal cancer cell lines (MCF7, HT29) (advisor, PhD of Molecular Medicine, TUMS)
- 16) Expression of C-MET in Gastric Adenoma carcinomas in patients referring to Tehran hospitals between years 1387-1388 using Tissue Microarray (resident (SpR) of Pathology, IUMS)

Current teaching lectures, Iran University of Medical Sciences:

1. General pathology, for undergraduate students (Medical students)
2. Cancer immunology, Molecular basis of cancer, advanced immunology, general pathology, molecular techniques, immunohistochemistry, CISH, for post graduate students (PhD and MSc students):

Previous teaching experience:

- 1) Supervision of clinical research fellows (Surgery, gynaecology), and MSc student (oncology)), University of Nottingham: 2005
- 2) Demonstration for BioMed Science students, University of Nottingham: 2004
- 3) Demonstration for pharmacy students, University of Nottingham: 2004
- 4) Supervision of undergraduate students for lab skills in the Department of Clinical Oncology during PhD course: 2001-2004
- 5) Short courses for administrative and health professionals in the Department of School Health: 1999
- 6) Running workshops and short courses for health allies in health centres

CONFERENCES (Selected):

1. British Association of Cancer Research, July 2001, Leeds
2. British Association of Cancer Research, July 2002, Glasgow
3. Progress in vaccine against Cancer (PIVAC), July 2002, Nottingham
4. American Association of Cancer Research, March 2003.
5. 15th European Immunology Congress (EFIS), 2003.
6. American Association of Immunology (AAI), May 2003
7. British Association of Cancer Research (BACR), July 2003, Bournemouth
8. Federation of European Cancer Societies (FECS), ECCO 12, September 2003, Copenhagen.
9. British Society of Immunology (BSI) December 2003, Harrogate.
10. American Association of Cancer Research (AACR) March 2004, Orlando
11. Cancer Detection and Prevention Strategy, Jan 2004, Nice, France.
12. British Cancer Research Meeting (BCRM), Manchester, June 2004.
13. European Association of Cancer Research (EACR), July 2004, Innsbruck, Austria.
14. NCRI (National Cancer Research Institute), Birmingham, Oct 2005.
15. ECCO13 (European Cancer Conference), Paris, Nov 2005.
16. International Royan Congress, Sep 2006, Tehran International Royan Congress, Sep 2006, Tehran
17. Second Congress of Breast, 9-10 Nov, 2006, Tehran
18. 8th Congress of Iranian Society of Pathology, 2-4 Nov 2006, Tehran

19. CD59 as an independent indicator of poor prognosis in breast carcinomas, a tissue microarray study of 520 patients, presented in 8th Congress of Iranian Society of Pathology, 2-4 Nov 2006, Tehran
20. Breast Cancer congress, Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Feb 2007.
21. Lectures in Pathology CME, Iran University of Medical Sciences, May 2007
22. Expression of Glycolipid Monoclonal Antibody, SC104, improved survival in colorectal cancer patients, A tissue microarray study. Madjd Z, Watson NF, Ellis IO, Durrant LG. The 9th annual Congress of Iranian Pathology, Nov 2007.
23. Can Breast Cancer Stem cells resist Apoptosis through the regulation of Bcl2? **Madjd z**, Zare Mehrjerdi,.. The 9th annual Congress of Iranian Pathology, Nov 2007.
24. Can complement regulatory proteins use as a target for cancer vaccine in breast cancer patients? **Madjd Z**, Durrant LG, Pinder SE, APPCC, Nov 2007
25. Will Cancer Stem cells use as a new target for cancer treatment? International anatomy Conference, Cell therapy, May 2008
26. Lectures in Pathology CME, Iran University of Medical Sciences, May 2008
27. Cancer Stem cells resist Apoptosis through the regulation of Bcl2. EACR 20, Lyon, France, July 2008
28. Human embryonic stem cell genes OCT4 and NANOG are expressed in breast, brain and thyroid carcinomas compared to testicular carcinoma, 4th international breast cancer conference, Feb 2009, Tehran
29. Prevalence of cancer stem cells and its association with clinical outcome and prognostic factors in breast cancer patients, ncri, Birmingham, Oct 2009, UK
30. Expression of embryonic stem cell markers, OCT4 and NANOG, in breast, thyroid, brain and colorectal carcinomas, ncri, Birmingham, Oct 2009, UK
31. The clinical significance of stem cell marker CD133 in pediatric solid tumours, a study using Tissue microarray, Pathology congress, Tehran, Oct 2011.
32. High expression of stem cell marker, ALDH1 is associated with mutated BRCA1 in invasive breast carcinomas, 7th NCRI (National Cancer Research Institute) Cancer Conference, Nov 2011, UK
33. Expression and clinical significance of stem cell marker CD133 in pediatric solid tumours, a study using Tissue microarray, 7th NCRI Cancer Conference, Nov 2011, UK
34. Do clinical and demographic features of patients with upper-gastrointestinal cancer affect their health-related quality of life? 7th NCRI Cancer Conference, Nov 2011, UK
35. Analysis of EMSY, a novel BRCA2-link protein, in primary breast tumors; a study using tissue microarray, Breast Cancer Conference, Shahid Beheshti Uni, Cancer research centre, Tehran, Feb 2012
36. 12th annual meeting of International Society for Stem Cell Research (ISSCR), Vancouver, Canada, June 2014.